David Bond, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH, briefly discusses the promising results of the SWOG S1826 trial (NCT03907488), which is comparing the safety and efficacy of nivolumab (N)-AVD versus brentuximab vedotin (BV)-AVD in patients with advanced stage classical Hodgkin lymphoma (cHL). This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.